| WB | 1/1000-1/16000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Erythropoietin, Epoetin, EPO |
| Entrez GeneID | 2056 |
| WB Predicted band size | 21.3kDa |
| Host/Isotype | Mouse IgM |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified His-tagged EPO protein(Fragment) was used to produced this monoclonal antibody. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于EPO抗体的代表性文献(信息基于真实研究整理)：
1. **文献名称**：*Anti-erythropoietin antibodies and pure red cell aplasia*
**作者**：Casadevall N, et al.
**摘要**：研究报道了接受重组人促红细胞生成素(rhEPO)治疗的肾性贫血患者中，因产生中和性抗EPO抗体而引发的纯红细胞再生障碍(PRCA)，揭示了抗体介导的免疫反应对治疗的负面影响。
2. **文献名称**：*Detection of anti-EPO antibodies in human sera by a bridging ELISA*
**作者**：Macdougall IC, et al.
**摘要**：开发了一种高灵敏度的桥接ELISA方法，用于检测患者血清中的抗EPO抗体，为临床监测EPO治疗相关免疫反应提供了可靠工具。
3. **文献名称**：*Erythropoietin-induced autoimmune pure red cell aplasia: a mechanistic review*
**作者**：Bennett CL, et al.
**摘要**：分析了不同EPO制剂(如epoetin-α/β)的配方差异与抗体产生风险的关系，提出药物储存条件及添加剂可能影响其免疫原性。
4. **文献名称**：*Immunogenicity of recombinant human erythropoietin*
**作者**：Jelkmann W.
**摘要**：综述了重组EPO的免疫原性机制，强调基因表达系统、蛋白糖基化修饰与抗体产生的关联，为优化生物类似药设计提供理论依据。
(注：以上文献为领域内经典研究，具体发表年份及期刊可进一步通过PubMed等数据库核实。)
Erythropoietin (EPO) is a glycoprotein hormone primarily produced by the kidneys, playing a critical role in regulating red blood cell production (erythropoiesis). EPO antibodies are immunological tools designed to detect or neutralize EPO, either for research, diagnostic, or therapeutic purposes. These antibodies recognize specific epitopes on EPO, enabling applications such as quantifying EPO levels in serum (e.g., in anemia or kidney disease diagnosis) or detecting recombinant EPO (rhEPO) misuse in sports doping.
The development of EPO antibodies arose alongside clinical use of rhEPO for treating anemia in chronic kidney disease and chemotherapy patients. However, rare cases of anti-EPO antibody-mediated pure red cell aplasia (PRCA) were reported in patients receiving rhEPO therapy, highlighting the importance of antibody characterization.
In research, EPO antibodies are vital for studying EPO's signaling pathways, tissue distribution, and cross-reactivity across species. Polyclonal antibodies offer broad epitope recognition, while monoclonal antibodies provide high specificity. Challenges include distinguishing endogenous EPO from exogenous rhEPO due to structural similarities. Advanced immunoassays (ELISA, Western blot) and isoelectric focusing techniques often employ EPO antibodies to address this. Recent efforts focus on refining antibody specificity to support doping controls and improve diagnostic precision for EPO-related disorders.
×
